SCOLR drops PE plans
This article was originally published in The Tan Sheet
Executive Summary
SCOLR Pharma announces Feb. 6 it will no longer continue the development of a 12-hour CDT-based phenylephrine formulation. The Bellevue, Wash.-based firm says the recently completed non-optimized CDT-based extended release PE trial "provided valuable data but does not justify continued internal development." SCOLR Pharma's VP and Chief Technology Officer Stephen Turner says the firm plans to focus its resources on an extended release formulation of pseudoephedrine with the goal of filing an ANDA later this year...
You may also be interested in...
SCOLR Ready To Answer FDA Questions On 12-Hour Pseudoephedrine ANDA
FDA has raised questions on "minor" issues regarding SCOLR Pharma's proposed nonprescription 12-hour pseudoephedrine tablet, according to the firm
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.